The role of infection in the pathogenesis of idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 22, Issue 129, 2013, Pages 376-381

  Molyneaux, Philip L ^a,b   Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GANCICLOVIR; PLACEBO;

BACTERIAL INFECTION; DISEASE COURSE; DISEASE EXACERBATION; EPSTEIN BARR VIRUS INFECTION; FIBROSING ALVEOLITIS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; INFECTION; NONHUMAN; PATHOGENESIS; PNEUMOCYSTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TORQUE TENO VIRUS; VIRUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 84883341999     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00000713     Document Type: Review

References (47)

1. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835-839.
2. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-1512.
3. du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146.
4. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3: 293-298.
5. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
6. Richeldi L. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147-151.
7. Yang IV, Luna LG, Cotter J, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PloS One 2012; 7: e37708.
8. Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992; 146: 266-268.
9. Arase Y, Suzuki F, Suzuki Y, et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 2008; 14: 5880-5886.
10. Irving WL, Day S, Johnston ID. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 1993; 148: 1683-1684.
11. Meliconi R, Andreone P, Fasano L, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax 1996; 51: 315-317.
12. Bando M, Ohno S, Oshikawa K, et al. Infection of TT virus in patients with idiopathic pulmonary fibrosis. Respir Med 2001; 95: 935-942.
13. Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 1698-1702.
14. Vergnon JM, Vincent M, de Thé G, et al. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet 1984; 2: 768-771.
15. Manika K, Alexiou-Daniel S, Papakosta D, et al. Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24: 134-140.
16. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159: 1336-1341.
17. Kelly BG, Lok SS, Hasleton PS, et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 510-513.
18. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41: 2633-2640.
19. Lasithiotaki I, Antoniou KM, Vlahava VM, et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. PloS One 2011; 6: e27800.
20. Lok SS, Haider Y, Howell D, et al. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. Eur Respir J 2002; 20: 1228-1232.
21. Mora AL, Woods CR, Garcia A, et al. Lung infection with cherpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol 2005; 289: L711-L721.
22. Stoolman JS, Vannella KM, Coomes SM, et al. Latent infection by cherpesvirus stimulates profibrotic mediator release from multiple cell types. Am J Physiol Lung Cell Mol Physiol 2011; 300: L274-L285.
23. Naik PN, Horowitz JC, Moore TA, et al. Pulmonary fibrosis induced by gamma-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-beta. J Gerontol A Biol Sci Med Sci 2012; 67: 714-725.
24. Golden A, Bronk TT. Diffuse interstitial fibrosis of lungs; a form of diffuse interstitial angiosis and reticulosis of the lungs. AMA Arch Intern Med 1953; 92: 106-114.
25. Calabrese F, Kipar A, Lunardi F, et al. Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis. PloS One 2013; 8: e55715.
26. Kropski JA, Lawson WE, Blackwell TS. Right place, right time: the evolving role of herpesvirus infection as a "second hit" in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302: L441-L444.
27. Barton E, Mandal P, Speck SH. Pathogenesis and host control of gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011; 29: 351-397.
28. Isler JA, Skalet AH, Alwine JC. Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol 2005; 79: 6890-6899.
29. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1119-L1126.
30. Young LR, Pasula R, Gulleman PM, et al. Susceptibility of Hermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am J Respir Cell Mol Biol 2007; 37: 67-74.
31. Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 73-82.
32. Egan JJ, Adamali HI, Lok SS, et al. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med 2011; 2011: 240805.
33. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
34. Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: 93-100.
35. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109.
36. Huie TJ, Olson AL, Cosgrove GP, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010; 15: 909-917.
37. McMillan TR, Moore BB, Weinberg JB, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008; 177: 771-780.
38. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167-175.
39. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167.
40. Richter AG, Stockley RA, Harper L, et al. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 2009; 64: 692-697.
41. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of cotrimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-162.
42. Beasley V, Joshi PV, Singanayagam A, et al. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulm Dis 2012; 7: 555-569.
43. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PloS One 2010; 5: e8578.
44. Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010; 14: 9-59.
45. Friaza V, la Horra C, Rodri{dotless}́guez-Domi{dotless}́nguez MJ, et al. Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization. J Microbiol Methods 2010; 82: 98-101.
46. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-214
47. Molyneaux PL, Russell AM, Cox MJ, et al. The respiratory microbiome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: A5174.